Related Experiment Video

Updated: Mar 3, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease

Simon Glerup1, Rainer Schulz2, Ulrich Laufs3

  • 1Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark.

Basic Research in Cardiology
|April 26, 2017
PubMed

Insights

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDL-C, a key factor in heart disease. Recent research highlights PCSK9

Area of Science:

  • Cardiovascular Biology
  • Lipid Metabolism
  • Pharmacology

Background:

  • Ischemic heart disease is a leading global cause of death, often exacerbated by high LDL-C levels.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in regulating LDL-C by promoting LDL receptor degradation.
  • Recent advancements have elucidated the complex regulation of PCSK9 activity at multiple biological levels.

Purpose of the Study:

  • To review recent biological and clinical data concerning PCSK9.
  • To discuss the regulation of PCSK9, including its transcription, secretion, and extracellular inactivation.
  • To explore the extra-hepatic roles of PCSK9, particularly in cardiovascular cells.

Main Methods:

  • Literature review of recent biological and clinical studies on PCSK9.
  • Analysis of regulatory mechanisms influencing PCSK9 activity.
  • Examination of PCSK9's physiological and pathological roles in cardiovascular cells.

Main Results:

  • PCSK9 activity is tightly regulated through various mechanisms.
  • PCSK9 has significant roles beyond hepatocytes, impacting cardiovascular cells.
  • Approved PCSK9-targeting antibodies and ongoing clinical trials show promise in reducing cardiovascular events.

Conclusions:

  • PCSK9 is a crucial target for managing hypercholesterolemia and reducing cardiovascular risk.
  • Understanding PCSK9's multifaceted roles is essential for developing effective therapeutic strategies.
  • Further clinical data will clarify the long-term impact of PCSK9 inhibition on cardiovascular outcomes.

Keywords:
LDLLDL receptoroxLDL

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
529
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
599
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
776
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
347